Clinical Trial Update: Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating maintenance therapy with MGN1703 in small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• MGN1703 (MGN1703)

Snippet

Sponsor: Mologen AG | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED